Abstract
Since the completion of the Human Genome Project, increasing scrutiny has focused on patterns of genetic variation among global populations and their association with disease and human traits. This paper addresses emerging techniques to identify genetic differences, including admixture mapping and the use of ancestry informative markers (AIMS), towards controlling population substructure in genetic association studies. The paper discusses the need to reconcile statistical race used to determine genetic ancestry with phenotypic race in identifying and addressing ongoing health disparities among human populations. As DNA biobanking grows and standards for collecting phenotypic information are developed, clear understanding of the varied approaches to defining race and their implications will be imperative. Central to this explication will be an exploration of how genetic technologies inform current approaches to ancestry and their relevance for pharmacogenomic applications.
Keywords: DNA biobanks, genetic ancestry, health disparities, pharmacogenomics, race-based therapeutics
Current Pharmacogenomics and Personalized Medicine
Title: Defining Statistical Race and Phenotypic Race and Their Implications for Health Disparities
Volume: 7 Issue: 4
Author(s): S. S-J. Lee
Affiliation:
Keywords: DNA biobanks, genetic ancestry, health disparities, pharmacogenomics, race-based therapeutics
Abstract: Since the completion of the Human Genome Project, increasing scrutiny has focused on patterns of genetic variation among global populations and their association with disease and human traits. This paper addresses emerging techniques to identify genetic differences, including admixture mapping and the use of ancestry informative markers (AIMS), towards controlling population substructure in genetic association studies. The paper discusses the need to reconcile statistical race used to determine genetic ancestry with phenotypic race in identifying and addressing ongoing health disparities among human populations. As DNA biobanking grows and standards for collecting phenotypic information are developed, clear understanding of the varied approaches to defining race and their implications will be imperative. Central to this explication will be an exploration of how genetic technologies inform current approaches to ancestry and their relevance for pharmacogenomic applications.
Export Options
About this article
Cite this article as:
Lee S-J. S., Defining Statistical Race and Phenotypic Race and Their Implications for Health Disparities, Current Pharmacogenomics and Personalized Medicine 2009; 7 (4) . https://dx.doi.org/10.2174/187569209790112300
DOI https://dx.doi.org/10.2174/187569209790112300 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Pathophysiology of Type 2 Diabetes in Children and Adolescents
Current Diabetes Reviews Synthesis and Biological Potentials of Quinoline Analogues: A Review of Literature
Mini-Reviews in Organic Chemistry Brain Angiotensin and Cardiovascular Reactivity to Negative and Positive Emotional Stress
Current Hypertension Reviews Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Benefit of SERCA2a Gene Transfer to Vascular Endothelial and Smooth Muscle Cells: A New Aspect in Therapy of Cardiovascular Diseases
Current Vascular Pharmacology Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Hypovitaminosis D is Associated with Endothelial Dysfunction in Patients with Metabolic Syndrome
Current Vascular Pharmacology Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Carotid Intima Media Thickness and Beyond
Current Drug Targets - Cardiovascular & Hematological Disorders Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology